Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve.
Homa HematiMarzieh NosratiMandana HasanzadParham RahmaniSoroush FarimanMohadese SarabiSepideh ShirvaniParham SadeghipourShekoufeh NikfarPublished in: Iranian journal of pharmaceutical research : IJPR (2024)
Warfarin dosing with pharmacogenomics testing is currently not cost-effective. However, if the cost of genotyping tests decreases to $118, the ICER would become cost-effective.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- venous thromboembolism
- oral anticoagulants
- adverse drug
- clinical decision support
- aortic valve
- mitral valve
- heart failure
- high throughput
- genome wide
- aortic stenosis
- emergency department
- genetic diversity
- transcatheter aortic valve replacement
- gene expression
- electronic health record
- coronary artery disease
- ejection fraction
- drug induced